Plain-English translation of NCT06789679 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a third drug called S-1 to a two-drug chemotherapy regimen (albumin-bound paclitaxel and gemcitabine) works better for treating pancreatic cancer. Half of the 128 participants will receive the two-drug combination, and half will receive all three drugs. The study will follow participants over time to see how well each treatment works and what side effects occur.
Pancreatic cancer is difficult to treat and patients need better options. Researchers want to know if adding this third medication to the standard two-drug chemotherapy might help patients live longer or respond better to treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive chemotherapy infusions through an IV on a regular schedule — either every 3 weeks or every 2 weeks, depending on which treatment group you are randomly assigned to. You may also take an oral medication (a pill) depending on your group. You will have regular clinic visits for blood tests, scans, and check-ups, and the research team will follow up with you every three months by phone or messaging to track how you are doing. The study will continue until your cancer progresses, you choose to stop, or the study ends.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China